Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTI-291 multiple-dose safety and PK study in Parkinson's disease with GBA1 mutation
NL-OMON23923Active, not recruiting
- Sponsor
- Lysosomal Therapeutics
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of pariceract in Parkinson's disease (PD) (4 arms), sponsored by Lysosomal Therapeutics. Primary endpoint: Safety and tolerability endpoints. Started Dec 2017; status: active, not recruiting.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON23923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23923.